#161764

TOV-21G cell line

Please Enter Your Email ID
Email ID

Cat. #161764

TOV-21G cell line

Cat. #: 161764

Organism: Human

Tissue: Derived from solid tumors of ovarian cancer patient

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Provencher et al. 2000. In Vitro Cell.Dev.Biol.-Animal (36): 357–361. PMID:10949993

Tool Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: TOV-21G cell line
  • Alternate name: TOV-21G
  • Cancer: Gynaecologic cancer
  • Research fields: Cancer
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from solid tumors of ovarian cancer patient
  • Donor: Grade 3 - Stage IIIC; Mutations: TGF-b-II Exon 2, K-RAS2; Pre-treatment
  • Crispr: No
  • Receptors of note: No
  • Description: Spontaneous immportilized epithelial ovarian cancer cell line derived from a patient never exposed to chemotherapy or radiation therapy. Cell line retains cahracteristics of the original epithelial ovarian cancers from which it was derived.

References

  • Raspaglio et al. 2023. Cancers (Basel). 18
  • 15(8):2361. PMID: 37190289 Yee et al. 2022. Front Bioeng Biotechnol. 10
  • 10:836984. PMID: 35223797 Brodeur et al. 2021. Sci Rep. 14
  • 11(1):18183. PMID: 34521878 Buttarelli et al. 2022. J Exp Clin Cancer Res. 4
  • 41(1):50. PMID: 35120576